CompletedNCT02748044Updated Apr 22, 2016

Validation of the Utility of Rare Disease Intelligence Platform

An interventional study of CC-Cruiser in Cataract and Artificial Intelligence, sponsored by Sun Yat-sen University. Completed at 4 sites in China. Open to participants aged Up to 80 Years. Per ClinicalTrials.gov, last updated 2016-04-22.

Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Diagnostic

Phase: Not applicable
Study type: Interventional
Enrollment: 53
Allocation: Not applicable
Ages: Up to 80 Years
Sex: All

Study summary

The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. The artificial intelligence for systematic clinical application has not yet been successfully validated. Currently, the main prevention strategy for rare diseases is to build specialized care centers. However, these centers are scattered, and their coverage is insufficient, resulting in inadequate health care among a large proportion of rare disease patients. Here, the investigators use "deep learning" to create CC-Cruiser, an intelligence agent involving three functional networks: "pick-up networks" for diagnostics, "evaluation networks" for risk stratification and "strategist networks" to provide assisted treatment decisions. The investigator also establish a cloud intelligence platform for multi-hospital collaboration and conduct clinical trial and website-based study to validate its versatility.

Conditions studied

Cataract
Artificial Intelligence

Browse trials for

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 53 is below the median of 80 across 1,155 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: Up to 80 Years
Sexes eligible: All
Accepts healthy volunteers: No

Inclusion criteria

Patients who underwent ophthalmic examination of the eye and recorded their ocular information in the collaborating hospital.

Exclusion criteria

Exclusion Criteria:

Study design

Phase: Not applicable
Primary purpose: Diagnostic
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrollment: 53 participants (actual)

Study arms

Experimental
Eligible patients for CC-Cruiser test
Device: CC-Cruiser

Interventions

DeviceCC-Cruiser
An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts

What researchers measure

Primary outcomes

The proportion of accurate, mistaken and miss detection of CC-Cruiser.
Time frame: Up to 4 years

Study locations

4 sites

Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, Guangdong 510060, China
Department of Ophthalmology, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong 510080, China
Department of Ophthalmology, First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine
Guangzhou, Guangdong 510405, China
Department of Ophthalmology, Qingyuan People's Hospital
Qingyuan, Guangdong 511518, China

References and documents

Publications

Lin H, Long E, Chen W, Liu Y. Documenting rare disease data in China. Science. 2015 Sep 4;349(6252):1064. doi: 10.1126/science.349.6252.1064-b. No abstract available. PubMed 26339020 ↗
Lin H, Ouyang H, Zhu J, Huang S, Liu Z, Chen S, Cao G, Li G, Signer RA, Xu Y, Chung C, Zhang Y, Lin D, Patel S, Wu F, Cai H, Hou J, Wen C, Jafari M, Liu X, Luo L, Zhu J, Qiu A, Hou R, Chen B, Chen J, Granet D, Heichel C, Shang F, Li X, Krawczyk M, Skowronska-Krawczyk D, Wang Y, Shi W, Chen D, Zhong Z, Zhong S, Zhang L, Chen S, Morrison SJ, Maas RL, Zhang K, Liu Y. Lens regeneration using endogenous stem cells with gain of visual function. Nature. 2016 Mar 17;531(7594):323-8. doi: 10.1038/nature17181. Epub 2016 Mar 9. Erratum In: Nature. 2017 Jan 26;541(7638):558. doi: 10.1038/nature19831. PubMed 26958831 ↗

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Apr 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT02748044
Lead sponsor: Sun Yat-sen University
Collaborators: Ministry of Health, China, Xidian University
Responsible party: Erping Long (Principal Investigator, Home for Cataract Children, Zhongshan Ophthalmic Center, Sun Yat-sen University) — Principal investigator
First posted: Apr 22, 2016
Start date: Jan 2012
Primary completion: Apr 2016
Completion: Apr 2016
Last update: Apr 22, 2016

Study contacts

Haotian Lin, M.D., Ph.D

study director · Zhongshan Ophthalmic Center, Sun Yat-sen University

Yizhi Liu, M.D., Ph.D

study chair · Zhongshan Ophthalmic Center, Sun Yat-sen University

Erping Long, M.D., Ph.D

principal investigator · Zhongshan Ophthalmic Center, Sun Yat-sen University

Oversight

Data monitoring committee: Yes

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cataract→

Other studies from this sponsor

Sun Yat-sen University

Start the discussion